ORLANDO – The dipeptidyl peptidase (DPP-4) inhibitor sitagliptin seems to confer multiple benefits in type 1 diabetics with suboptimal glycemic control, according to early results released at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA). In a pilot study that included 20 type 1 patients, four weeks’ treatment with sitagliptin led to decreased hemoglobin (Hb)A1c and mean blood glucose levels and total daily insulin doses…

Credits to:Health News from Medical News Today

Related Posts

• Obese Type 2 Diabetes Patients Have Long-Term Benefits From Intensive Lifestyle Intervention
  If obese/overweight patients with diabetes Type 2 are helped to get fit, lose weight and control blood glucose levels, their long-term outlook improve...
• Type 2 Diabetes Linked to Alzheimer’s Disease
  The research just keeps piling up -- more and more scientists are reporting a possible link between type 2 diabetes and Alzheimer's Disease (and simil...
• Pop Quiz: How much do you know about type 2 diabetes?
  How much do you really know about type 2 diabetes? Get out your number 2 pencils and see how you do.1. In adults, type 2 diabetes accounts for about w...
• About the Nutrition Data Type 2 Diabetes Blog
  The Diabetes Blog is your source for inspiration, insight, and the most up-to-date information about Type 2 diabetes. Learn how Nutrition Data's power...
• Sepsis Linked To Mental And Physical Decline In Older Patients
  A new US study found that older patients who survived severe sepsis were more likely to experience signficant mental and physical decline, in some c...